Integragen ALINT.PA · EUR

Its shares trade on Euronext Paris under the ticker ALINT.PA. It has been listed since 18 June 2010. In the fiscal year to 31 December 2025, it reported revenue of €5.0m and a net loss of €2.7m. At that date it held total assets of €2.8m and shareholders' equity of −€909,000.

IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jean StephenneChairman of the Board
• Mr. Bernard CourtieuChief Executive Officer, since 2007
• Mr. Pierre FlamantAdministrative and Finance Director, Member of the Management committee
• Mr. Emmanuel MartinChief Operating Officer, Member of the Management committee
• Mrs. Catherine DavidMember of the Management committee, Quality Director
• Mr. Berengere GeninMember of the Management committee, Head of Academics, Research & Hospitals Business unit, since 2020
• Mr. Larry YostMember of the Management committee, Director of the American subsidiary IntegraGen, Inc., since 2014
• Mr. Alain DeclercqDirector
• Mr. Jean-pol DetiffeDirector
• Mr. Louis-victor DelouvrierInvestor Relations, Financial Communications, since 2022

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.